"Mitotane" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.
| Descriptor ID |
D008939
|
| MeSH Number(s) |
D02.455.526.439.681
|
| Concept/Terms |
Mitotane- Mitotane
- o,p-DDD
- Mytotan
- ortho,para-DDD
- ortho,para DDD
|
Below are MeSH descriptors whose meaning is more general than "Mitotane".
Below are MeSH descriptors whose meaning is more specific than "Mitotane".
This graph shows the total number of publications written about "Mitotane" by people in this website by year, and whether "Mitotane" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mitotane" by people in Profiles.
-
Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience. J Clin Endocrinol Metab. 2022 04 19; 107(5):1239-1246.
-
American Association of Clinical Endocrinology Disease State Clinical Review on the Evaluation and Management of Adrenocortical Carcinoma in an Adult: a Practical Approach. Endocr Pract. 2020 Nov; 26(11):1366-1383.
-
Update on adrenocortical carcinoma management and future directions. Curr Opin Endocrinol Diabetes Obes. 2017 Jun; 24(3):208-214.
-
Adrenocortical Cancer: A Molecularly Complex Disease Where Surgery Matters. Clin Cancer Res. 2016 Oct 15; 22(20):4989-5000.
-
Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma. Cancer Res. 2015 Oct 01; 75(19):4131-42.
-
High (18)F-FDG uptake by the remaining adrenal gland four months after surgery and initiation of mitotane treatment in two patients with adrenocortical carcinoma. Hell J Nucl Med. 2011 May-Aug; 14(2):168-72.
-
Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Ann Surg Oncol. 2010 Jan; 17(1):263-70.
-
Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma. Surgery. 2007 Dec; 142(6):867-75; discussion 867-75.
-
Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery. 1995 Dec; 118(6):1090-8.
-
Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer. 1994 Mar 01; 73(5):1533-5.